In addition, we recently reported a dramatic downregulation of EZH2 in decompensated RV from PAH patients and animal models as well as an increased expression of EZH2 in animals presenting improved cardiac function secondary to therapeutic intervention [16]. Here, EZH2 is linked to pulmonary arterial hypertension.